Department of Skin and Venereal Diseases, University of Ioannina Medical School, Ioannina, Greece.
Eur J Dermatol. 2012 May-Jun;22(3):363-9. doi: 10.1684/ejd.2012.1717.
High-dose intravenous immunoglobulin (IVIg) has only been sporadically used in the treatment of bullous pemphigoid (BP), as it is suggested as an adjuvant to systemic corticosteroids in progressive disease or when life-threatening complications are of concern with other therapeutic interventions. The aim of the present study was to report our observations in the treatment of adult BP patients with IVIg, in association with a focused literature review. In our Department we identified five patients (4 women, 1 man) who had received IVIg for BP relatively early in the course of their disease. These cases were added to the 36 adequately documented ones reported in the literature. Most of these patients (33/41) responded to treatment with IVIg and 7/33 responders remained clear one year after the onset of IVIg. However, the time for effective disease control after IVIg treatment depended positively on disease duration before treatment (P<0.01). In conclusion, despite the limited experience with its use, IVIg seems to be a useful therapeutic alternative to conventional modalities for selected BP patients, particularly if it is initiated promptly after BP diagnosis.
高剂量静脉注射免疫球蛋白（IVIg）仅在治疗大疱性类天疱疮（BP）时偶尔使用，因为它被建议作为系统性皮质类固醇的辅助治疗，用于进展性疾病或当其他治疗干预措施存在危及生命的并发症时。本研究的目的是报告我们在治疗成人 BP 患者时使用 IVIg 的观察结果，并进行了重点文献复习。在我们的科室中，我们确定了 5 名（4 名女性，1 名男性）在疾病早期接受 IVIg 治疗的 BP 患者。这些病例被添加到文献中报道的 36 例有充分记录的病例中。这些患者中的大多数（33/41）对 IVIg 治疗有反应，7/33 名有反应者在开始 IVIg 治疗一年后仍保持无病状态。然而，IVIg 治疗后有效控制疾病的时间与治疗前疾病持续时间呈正相关（P<0.01）。总之，尽管 IVIg 的使用经验有限，但它似乎是一种有用的治疗选择，可替代传统治疗方法，用于某些 BP 患者，特别是在 BP 诊断后立即开始治疗时。
